Form 4: Adicet Bio, Inc.: Chief Medical Officer Acquires 750,000 Stock Options

Julia D. Maltzman, Chief Medical Officer of Adicet Bio, Inc., acquired 750,000 stock options on January 31, 2025, exercisable at $0.885 per share.

Summary

• On January 31, 2025, Julia D. Maltzman, the Chief Medical Officer of Adicet Bio, Inc., was granted 750,000 stock options.
• The exercise price for these options is $0.885 per share.
• The options vest over time, with 25% vesting on December 7, 2025, and the remainder vesting monthly over the following 36 months, contingent upon continued service with Adicet Bio.
• The options expire on January 30, 2035.

Sentiment

Score: 7

Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral to positive as it indicates alignment of management with shareholder interests. The sentiment is moderately positive as it reflects standard compensation practices.

Positives

• The grant of stock options to the Chief Medical Officer aligns her interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.

Future Outlook

The vesting schedule of the options is contingent upon the Reporting Person maintaining a service relationship with the Issuer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, indicating that the company is incentivizing its executives to create long-term value.

Key Dates

Keywords

stock options, Adicet Bio, Chief Medical Officer, Form 4, beneficial ownership, equity securities, Maltzman, ACET